Menu

Blog

Archive for the ‘biotech/medical’ category: Page 507

Mar 13, 2023

First longevity clinical study design fetches FDA approval

Posted by in categories: biotech/medical, life extension

Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.

Longevity. Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.

Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.

Mar 13, 2023

Reduced Blood Pressure: Was It Caused By Lung Muscle Training?

Posted by in categories: biotech/medical, genetics

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.

Continue reading “Reduced Blood Pressure: Was It Caused By Lung Muscle Training?” »

Mar 13, 2023

An Introduction to Neuroinformatics

Posted by in categories: biotech/medical, neuroscience

Details

The goal of brain imaging is to provide in-vivo measures of the human brain to better understand how the brain is structured, connected and functions.
In this talk, we will discuss how to analyze brain imaging data in order to make sense of the large amount of data that comes out of the scanner.

Continue reading “An Introduction to Neuroinformatics” »

Mar 13, 2023

New MIT/Caltech Ingestible Sensor Could Help Doctors Pinpoint GI Difficulties

Posted by in categories: biotech/medical, education, engineering

The sensor sends out its location as it moves through the GI tract, revealing where slowdowns in digestion may occur.

Engineers at MIT

MIT is an acronym for the Massachusetts Institute of Technology. It is a prestigious private research university in Cambridge, Massachusetts that was founded in 1861. It is organized into five Schools: architecture and planning; engineering; humanities, arts, and social sciences; management; and science. MIT’s impact includes many scientific breakthroughs and technological advances. Their stated goal is to make a better world through education, research, and innovation.

Mar 13, 2023

Scientists create mice with two fathers after making eggs from male cells

Posted by in categories: bioengineering, biotech/medical, food, genetics

https://www.youtube.com/watch?v=2JsgnlBffCA

https://gotopnews.com/post/1979903

Scientists created mice with two biological dads by producing eggs from male cells, which is a development that opens radical new possibilities for reproduction. Progress can ultimately pave way for treatments for severe infertility forms and increase possibility of attracting couples of same gender to have a biological child in future. Hayashi, who presented development at the third International Human Genome Regulation Summit at Francis Crick Institute in London on Wednesday, predicts it would be technically possible to create a human egg from a male skin cell in ten years. Considering that human eggs did not create eggs, he argued this timeline was optimistic. Previously, scientists have created mice technically with a detailed step chain, including genetic engineering. This is first time that can be applied first time, eggs were raised from male cells and pointing to an important progress. He was trying to reproduce with human cells, but there would be important obstacles for use of eggs grown in laboratory clinical purposes, including creating safety. “In terms of technology, it will be possible even in 10 years in 10 years, ve he personally added that the technology used clinically to allow two men to have a baby. Orum I don’t know if they are ready reproduction,” he said.“This is a question not only for the scientific program, but also[society].” Technique, X chromosome is missing or partially missing a copy of the turner syndrome, including women with severe infertility forms can be applied to treat and Hayashi, this application is the primary motivation for research, he said. Others argued that translating technique into human cells may be challenging. Human cells need much longer agricultural periods to produce a mature egg, which can increase the risk of undesirable genetic changes. Profess George Daley, the Dean of Harvard Medical Faculty, described the study as “fascinating„ but other researches also showed that creating gamet creating from human cells in laboratory is more difficult than mouse cells.said. The study, which was sent to be leading magazine, was based on a number of complex steps to transform skin cell that carries the combination of male XY chromosomes into an egg. Men’s skin cells were re-programmed into a stem cell-like condition to form the induced pluripotent root cells. Then the Y chromosome of these cells was deleted and changed and ” borrowed from another cell to produce IPS cells with two identical X chromosome. Hayashi said, ” The trick, greatest trick, the reproduction of X chromosome,” he said. ” We really tried to establish a system to replicate the X chromosome.” Finally, cells were grown in an ovary organoid with a cultural system designed to replicate the conditions within ovary. When Yumurtas were fertilized with normal sperm, scientists obtained approximately 600 embryos implanted in the mice, which resulted in birth of seven mouse offspring. ‘Efficiency was lower than the efficiency obtained by normal female-derived eggs, where approximately 5% of the embryos continued to produce a lively birth. Baby mice looked healthy, had a normal life, and as an adult continued to the offspring. ” They look good, they grow normal, they become a father, Hay Hayashi said. He and his colleagues are now trying to increase the creation of eggs grown in the laboratory using human cells. Working on Gamets grown in the laboratory at the University of California Los Angeles, Prof Amander Clark said that it would be a ” big jump in, because scientists have not yet created human eggs from women’s cells. Scientists have created the premises of human eggs, but so far, cells, mature eggs and sperm, a critical cell division step, which has stopped development before the point of meiosis. It can be 10 years or 20 years.”

Mar 13, 2023

Ray Kurzweil says We’ll Reach IMMORTALITY by 2030 | The Singularity IS NEAR

Posted by in categories: biotech/medical, genetics, life extension, nanotechnology, Ray Kurzweil, robotics/AI, singularity

Ray Kurzweil — The Singularity IS NEAR — part 2! We’ll Reach IMMORTALITY by 2030
Get ready for an exciting journey into the future with Ray Kurzweil’s The Singularity IS NEAR — Part 2! Join us as we explore the awe-inspiring possibilities of what could be achieved before 2030, including the potential for humans to reach immortality. We’ll dive into the incredible technology that could help us reach this singularity and uncover what the implications of achieving immortality could be. Don’t miss out on this fascinating insight into the future of mankind!
In his book “The Singularity Is Near”, futurist and inventor Ray Kurzweil argues that we are rapidly approaching a point in time known as the singularity. This refers to the moment when artificial intelligence and other technologies will become so advanced that they surpass human intelligence and change the course of human evolution forever.

Kurzweil predicts that by 2030, we will reach a crucial milestone in our technological progress: immortality. He bases this prediction on his observation of exponential growth in various fields such as genetics, nanotechnology, and robotics, which he believes will culminate in the creation of what he calls “nanobots”.

Continue reading “Ray Kurzweil says We’ll Reach IMMORTALITY by 2030 | The Singularity IS NEAR” »

Mar 12, 2023

Knots smaller than human hair make materials unusually tough

Posted by in categories: biotech/medical, nanotechnology

In the latest advance in nano-and micro-architected materials, engineers at Caltech have developed a new material made from numerous interconnected microscale knots.

The make the material far tougher than identically structured but unknotted materials: they absorb more energy and are able to deform more while still being able to return to their original shape undamaged. These new knotted materials may find applications in biomedicine as well as in aerospace applications due to their durability, possible biocompatibility, and extreme deformability.

Continue reading “Knots smaller than human hair make materials unusually tough” »

Mar 12, 2023

Retro Bio’s $180m backer finally revealed

Posted by in categories: biotech/medical, finance, life extension, nuclear energy, robotics/AI

Retro Biosciences’ mysterious backer has finally been revealed!


In 2021 the longevity industry received one of its largest investments to date, with a $180m investment being made into the pharmaceutical start known as Retro Biosciences, or Retro Bio for short. Not only was this investment cause for celebration within the field of regenerative medicine, but it also came with a tantalising mystery, as the backer, or indeed backer, did not make themselves publicly known. It was assumed that due to the secrecy involved, it was likely that this investment had come from a small number of individuals, potentially just a single backer. This mystery backer, combined with the notable capital investment, led to much media attention at the time, and has since garnered a significant amount of interest in Retro Bio from both the general public and future potential financial backers. That was until last week, when the mystery backer finally decided that now was the right time to reveal their identity to the general public.

In an interview with MIT Technology review, American entrepreneur Sam Altman revealed that he was the sole backer for the pharmaceutical start-up, who single handily provided the entire $180m investment. Sam Altman, who primarily made his fortune in the tech industry (specifically through social media companies such as Loopt) has become somewhat of an angel investor for a slew of world changing, innovative companies which are involved in everything from artificial intelligence to nuclear energy. It is hoped that this significant single investment marks the beginning of a longevity tech boom, similar to what was seen during the dot-com boom (but hopefully without the disastrous ending).

Mar 11, 2023

Can you have thyroid cancer without knowing?

Posted by in category: biotech/medical

The thyroid is a small, butterfly-shaped gland at the base of the neck. It’s responsible for the hormones that control your heart rate, blood pressure, temperature and metabolism.

When thyroid cells grow abnormally, they can cause thyroid cancer. But because symptoms are vague and may mimic other less-serious conditions, it’s possible you could have thyroid cancer for months or even years without knowing it.

Thyroid cancer surgeon Nancy Perrier, M.D., explains how thyroid cancer can go unnoticed – and what you can do to catch it early when it’s easiest to treat.

Mar 11, 2023

Viral Vector Production Evolves to Meet Surging Demand

Posted by in category: biotech/medical

The potential for supply constraints also concerns industry analysts. For example, McKinsey analysts have warned that limited AAV vector capacity could delay the commercialization of new gene therapies, particularly those intended for larger patient populations.

Last March, a McKinsey article stated, “The majority of early viral-vector-based therapeutics were developed within the context of rare diseases. [Only small] quantities of viral vectors were required, particularly as most therapies were still in the clinical stage of development. Now, with the shift beyond ultrarare indications, viral vector manufacturing requires rapid expansion to be able to address these diseases in the commercial space.”

Page 507 of 2,560First504505506507508509510511Last